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Systemic immunoglobulin light-chain (AL) amyloidosis 7 is a progressive disease caused by the deposition of insoluble fibrils formed by the aggregation of circulating monoclonal light chains produced by a usually small-sized bone-marrow plasma cell clone (1 ) . This process causes organ dysfunction and ultimately leads to death. However, effective chemotherapy, which suppresses the production of the amyloidogenic light chain before irreversible organ damage has occurred, can significantly extend survival (2 ) . Thus, early diagnosis is critical in the management of patients with AL amyloidosis. The diagnosis relies on both the demonstration of amyloid deposits in tissues and on the identification of the plasma cell clone producing a light chain, which should be proved amyloidogenic by direct biochemical or immunohistochemical typing of the amyloid deposits. The amyloidogenic clonal plasma cell population can be detected either by bone marrow analysis or by the identification of a monoclonal light chain in the patient's serum and/or urine (3 ) . The identification and quantification of the amyloidogenic light chain is also necessary in the follow-up of patients with AL amyloidosis to assess the hematologic response to therapy (3 ) . We investigated the optimal strategy to detect the amyloidogenic light chains, maximizing the diagnostic sensitivity. We performed a prospective study on 121 consecutive patients with AL amyloidosis, in whom the amyloidogenic light chain was detected in the amyloid deposits by use of immuno-electron microscopy (4 ) to assess the diagnostic sensitivity of the quantitative assay of circulating free light chains (FLC), of a commercial semiautomated agarose gel electrophoresis immunofixation (IFE) assay, and of the highresolution agarose gel electrophoresis immunofixation (HR-IFE) technique developed at our referral center. We also assessed the contribution of urine analysis to the diagnosis.
Material and Methods
Study participants were 121 patients with biopsyproven systemic AL amyloidosis consecutively enrolled between January 2004 and May 2005. None of the patients was previously treated. All the patients had been referred to our institution because of suspected systemic amyloidosis, and the diagnosis of AL amyloidosis was confirmed at our center. In that same period of time, a total of 179 such patients were referred to our center and the diagnosis of AL amyloidosis was not confirmed in 58 (32%) of them. All the patients gave written informed consent, and the study was approved by the review board of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo. Mutations associated with hereditary amyloidoses were excluded by DNA analysis. The amyloid deposits were characterized in all patients by immunoelectron microscopy analysis of abdominal fat aspirates and/or organ biopsies (4 ) . Six patients (5%) were excluded from the calculation of the diagnostic sensitivity of the tests because HR-IFE detected a biclonal gammopathy.
Serum and urine HR-IFE was performed with anti-IgG, -IgA, -IgM, -and -antibodies (Dako) on gels freshly prepared at our laboratory, following basically the technique proposed by the Malmö group (5 ). Briefly, electrophoresis was performed in freshly prepared 1-mm thick agarose (SeaKem ME agarose, Cambrex Bio Science), 7.5 g/L in diethyl barbiturate buffer (75 mmol/L, pH 8.6, with calcium lactate 2 mmol/L). Custom dilution of the patient's serum, and 100-fold concentrated urine sample were placed in 5-mmwidth slits, and 20 V/cm was applied until albumin had migrated 6.5 cm. After electrophoresis, filter paper strips soaked with 50 L of appropriate antiserum were applied to each lane and incubated in a moist chamber for 1 h. The agarose plate was then washed 3 times with saline and once with deionized water, then dried and stained with Coomassie Blue R 250. With this method, the detection limit of a monoclonal component is 50 -150 mg/L in serum and 30 -100 mg/L in urine, depending on the intensity of the polyclonal background. Semiautomated serum and urine IFE was performed with a commercial Hydragel 2IF/BJ(HR) kit on a Hydrasys apparatus (Sebia). The detection limit reported by the manufacturer varies from 120 -250 mg/L, according to the migration of the monoclonal component and to the intensity of the polyclonal background. Serum FLC concentration was measured by latexenhanced immunoassay (The Binding Site) on a Behring BN II (Dade Behring) nephelometer. The reference intervals for and FLC are 3.3-19.4 mg/L and 5.7-26.3 mg/L, respectively, and the / ratio diagnostic range is 0.26 -1.65 (6 ) . A patient was classified as producing monoclonal or light chains according to an abnormal / ratio (6 ) . Serum FLC immunoassays have a limit of quantification of Ͻ1 mg/L (6 ) .
Differences in diagnostic sensitivity were tested for statistical significance by Fisher exact test, and CIs were determined by the exact binomial distribution.
To assess disease severity, the number and type of organs affected by amyloidosis and the cardiac stage, based on serum N-terminal pronatriuretic peptide type B (NT-proBNP) and cardiac troponin I (cTnI), were recorded in patients in whom the amyloidogenic light chain was not identified by both serum IFE and HR-IF, and in those in whom it was missed by assay of the combination of FLC / ratio and serum IFE. Patients with both NT-proBNP Յ332 ng/L and cTnI Ͻ0.1 g/L were listed as cardiac stage I, those with NT-proBNP Ͼ332 ng/L or cTnI Ն0.1 g/L were defined as cardiac stage II, and patients with both NTproBNP Ͼ332 ng/L and cTnI Ͼ0.1 g/L were defined as cardiac stage III (7 ).
Results
In 6 of the 121 patients with AL in whom the amyloidogenic light chain was identified by immuno-electron microscopy in the amyloid deposits, HR-IFE revealed a biclonal gammopathy (Table 1 ). In 4 of these patients, the FLC / ratio correctly identified the light chain type constituting the amyloid deposits, whereas highresolution IFE did not identify monoclonal light chains in the urine of 2 patients (no. 117 and 118), and in 2 patients (no. 116 and 121) the opposite light chain was identified. In all the remaining 115 patients, HR-IFE detected the monoclonal amyloidogenic light chain in serum and/or urine and, in all patients, the type of light chain detected corresponded to that identified by immuno-electron microscopy as forming the amyloid fibrils. The amyloidogenic light-chain type was in 30 patients (26%) and in 85 patients (74%).
The diagnostic sensitivity of the tests is reported in Table 2 . In 6 patients (5%) the HR-IFE detected the amyloidogenic light chain only in urine, and in 6 cases (5%) only in serum. Five of the 6 amyloidogenic light chains detected only in urine were of the type, whereas 5 of the 6 light chains detected only in the serum were . The diagnostic sensitivity of both immunofixation techniques was significantly lower for than for light chains in serum (HR-IFE 83% vs 99%, P ϭ 0.004; IFE 60% vs 87%, P ϭ 0.003). Conversely, the FLC assay performed better with than with amyloidogenic light chains (97% vs 69%, P ϭ 0.002). Notably, 5 patients with a FLC / ratio above the reference limit and Bence-Jones proteinuria did not show monoclonal light chains in serum with both immunofixation techniques (Table 3) .
One patient with a serum IgA monoclonal component, Bence-Jones protein, and amyloid deposits typed as had a / ratio of 1.72 ( FLC 146 mg/L and FLC 85 mg/L) and was incorrectly classified has having a clone by the FLC assay. This patient had renal failure (serum creatinine 221 mol/L) and polyclonal hypergammaglobulinemia that could account for the increase of both and FLC. In the overall population the median serum creatinine concentration was 103 mol/L (range: 44 -619 mol/L), and serum creatinine was within reference limits (males 115 mol/L, females 97 mol/L) in 65 patients (56%). In our patient population, renal failure did not significantly influence the diagnostic sensitivity of the / ratio, which was 78% (95% CI, 67%-87%) in patients with normal renal function and 73% (95% CI, 60%-84%) in patients with serum creatinine above the upper reference limit (P ϭ 0.58). Serum creatinine was not significantly higher in patients in whom the FLC / ratio failed to identify the amyloidogenic light chain (median 100 vs 114 mol/L, P ϭ 0.2). Recently, a new reference interval for the FLC / ratio (0.37-3.1) has been proposed for patients with abnormal kidney function (8 ) . The diagnostic sensitivity of this reference interval in the patients with serum creatinine above the upper reference limit was 71% (95% CI, 58%-83%), very similar to that obtained with the commonly used reference range. As expected, most of our patients had hypogammaglobulinemia, and only 14 (12%) were found to have polyclonal hypergammaglobulinemia by serum electrophoresis (␥ globulin concentrations of 18 -24 g/L). The diagnostic sensitivity of the / ratio was 71% (95% CI, 46%-90%) in patients with hypergammaglobulinemia and 79% (95% CI, 70%-86%) in the other patients (P ϭ 0.52).
The diagnostic sensitivity of commercial semiautomated serum and urine IFE was significantly higher than that of the serum FLC test (96% vs 76%, P Ͻ 0.001). The addition of serum IFE to the FLC / ratio enabled correct identification of the amyloidogenic light chain in all but 5 patients (4%), all of whom had a Bence-Jones protein detectable by urine IFE (Table  4 ). These 5 patients had symptomatic disease and were in need of prompt treatment. However, the combination of serum and urine IFE and of the FLC / ratio enabled correct identification of the amyloidogenic light chain in all the patients.
Discussion
The high-resolution immunofixation of serum and urine developed at our referral center enabled us to identify all amyloidogenic light chains in the study population. This result underlines the relevance of state-of-the-art techniques in the investigation of complex, rare diseases and the need for improving commercial immunofixation assays. However, this technique is not widely available. In our series, the diagnostic sensitivity of the FLC / ratio was 76%, that of commercial IFE of both serum and urine was 96%, and their combination correctly identified the amyloidogenic light chains in 100% of patients.
Previous studies on the diagnostic performance of the FLC assay in AL amyloidosis have led to different results. In the first 2 retrospective series by the United Kingdom National Amyloidosis Centre (9 ) and by the Mayo Clinic (10 ), the quantitative FLC assay showed a greater diagnostic sensitivity than the association of serum and urine immunofixation electrophoresis (98% vs 79% and 91% vs 81%, respectively). These results were not confirmed in a subsequent retrospective study by the investigators of the Boston Amyloid Program, who reported a lower diagnostic sensitivity of the FLC assay (75%) compared to immunofixation (96%) (11 ) , or in a subsequent study by the Mayo Clinic group (12 ) , in which the FLC assay and the combination of serum and urine immunofixation electrophoresis had a comparable diagnostic performance (diagnostic sensitivity 91% vs 95%, respectively). More recently, in a study from the Heidelberg group in which the study population included 11% of patients with multiple myeloma, the combination of serum and urine immunofixation had a slightly higher sensitivity than the FLC / ratio (92% vs 87%), and the 2 tests proved complementary (13 ) . It is worth noting that none of the previous studies was based on the unequivocal typing of the amyloidogenic protein constituting the amyloid deposits (1, 3 ) . This result is achievable using various techniques, including immuno-electron microscopy (4 ). In our series of consecutive patients the characterization of amyloidosis as AL type relied on immuno-electron microscopy results. Immuno-electron microscopy also confirmed that the light chain identified in the patients' serum and/or urine was actually amyloidogenic.
The observation of a higher diagnostic sensitivity of the FLC assay for than for light chains and of a lower resolution of serum immunofixation in patients with light chains in our series is in agreement with the results reported by the Boston and the Heidelberg groups (11, 13 ) . This difference may be due to the formation of aggregates of various size and electrophoretic mobility by light chains, resulting in the absence of a distinct electrophoretic band. This hypothesis is being tested at our center.
The introduction of the FLC assay also triggered a lively debate on the role of urine immunofixation in the diagnosis of AL amyloidosis. This issue was addressed in the study by Katzmann et al. on 110 patients with AL amyloidosis, in which the association of the FLC assay and serum immunofixation electrophoresis had a 99% diagnostic sensitivity and the addition of urine immunofixation electrophoresis did not improve this result (12 ) . In a subsequent retrospective study on 428 patients with plasma cell dyscrasia in whom a monoclonal light chain was detected in the urine by immunofixation, including 123 patients with AL amyloidosis, Katzmann and coworkers observed that the combination of the FLC assay and serum immunofixation identified a monoclonal light chain in 100% of the patients with amyloidosis (14 ) . However, this study included only patients with positive urine immunofixation, thus increasing the likelihood of an abnormal / ratio, because a high concentration of FLC is required to produce overflow proteinuria (15 ) . Studies performed on general hospital populations indicate that measurement of serum FLC may replace urine analysis in the initial screening of monoclonal gammopathies (16, 17 ) . The reported results of these studies showed that a false-positive / ratio was associated with polyclonal increases in immunoglobulin and with renal impairment. In our population, however, renal insufficiency and polyclonal hypergammaglobulinemia did not affect the diagnostic sensitivity of the / ratio. Also, the study by Bochtelr et al. (13 ) , performed in patients with AL amyloidosis, showed that renal insufficiency did not affect the diagnostic sensitivity of the FLC test. This discrepancy may be attributable to characteristics of the different patient populations. More recently, Dispenzieri et al. reported an unsatisfactory correlation between changes in FLC and urine monoclonal protein in multiple myeloma after chemotherapy, underlying the need for urine analysis in the follow-up of myeloma patients (18 ) . In the present series, the combination of serum IFE with the FLC assay detected the amyloid clone in 96% of the patients. Thus, our results indicate that, in patients with AL amyloidosis, urine immunofixation should also be performed to ensure optimal diagnostic sensitivity. Indeed, omitting urine immunofixation would have led to us missing 6% of patients with amyloidogenic clones, an important shortcoming given the severity of the disease and the need for early diagnosis. Only the combination of immunofixation electrophoresis of both serum and urine and the FLC assay was able to detect all the amyloidogenic clones. Semiautomated serum and urine IFE and the FLC test are widely available and should be combined for searching for a monoclonal component in patients with suspected AL amyloidosis.
Finally, it should be noted that in the present series 5% of the patients had a biclonal gammopathy and were not included in the assessment of the diagnostic sensitivity. In the 868 patients with AL amyloidosis evaluated at our center between 1986 and 2007 we observed a comparable proportion (6%) of cases with a biclonal gammopathy detectable with serum and urine HR-IFE. In the 6 patients with a biclonal gammopathy, the / ratio identified the amyloidogenic light chain in 4 cases (3 and 1 ), whereas immunofixation produced mixed results. However, in patients with a biclonal gammopathy, although an altered FLC / ratio may suggest which light chain is involved, only the direct typing of the amyloid deposits allows the unequivocal identification of the amyloidogenic light chain, which should be considered the marker of hematologic response to therapy.
The availability of new reliable tools, such as the FLC assay, has dramatically improved the management of AL amyloidosis. Nevertheless, our findings underline the complexity of this disease, which still does not allow reliance on only a few diagnostic tests. 
